Quarterly report pursuant to Section 13 or 15(d)

Significant Accounting Policies

v3.20.1
Significant Accounting Policies
3 Months Ended
Dec. 31, 2019
Significant Accounting Policies  
Significant Accounting Policies

2.  Significant Accounting Policies

Basis of Presentation

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended September 30, 2019 included in the Company’s Annual Report on Form 10-K (the “Annual Report”) filed with the SEC on January 10, 2020. The accompanying financial statements have been prepared by the Company in accordance with U.S. GAAP for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, the accompanying unaudited condensed consolidated financial statements for the periods presented reflect all adjustments, consisting of only normal, recurring adjustments, necessary to fairly state the Company’s financial position, results of operations and cash flows. The unaudited condensed consolidated financial statements for the interim periods are not necessarily indicative of results for the full year. The preparation of these unaudited condensed consolidated financial statements requires the Company to make estimates and judgments that affect the amounts reported in the financial statements and the accompanying notes. The Company’s actual results may differ from these estimates under different assumptions or conditions.

Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s condensed consolidated financial statements relate to the valuation of share-based compensation, the valuation of licenses, the fair value of warrant liabilities and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.

Restatement of Previously Issued Unaudited Financial Statements

As previously disclosed in the Annual Report, the Company determined the accounting treatment and valuations pertaining to the PATrOL™ technology license acquired during the three months ended December 31, 2018 should be modified. The Annual Report disclosed that the change in accounting treatment and valuations resulted in an increase in total operating expenses of approximately $0.9 million on the Company’s consolidated statements of operations for the fiscal year ended September 30, 2019 and a decrease in intangible assets of approximately $1.5 million on the Company’s consolidated balance sheet as of and for the fiscal year ended September 30, 2019, as well as a decrease in total operating expenses of approximately $0.3 million on the Company’s consolidated statements of operations in connection with the adjustment of the valuation of certain share-based awards for the fiscal year ended September 30, 2019.  

License Agreement with Carnegie Mellon University

On December 17, 2018, the Company entered into a License Agreement with Carnegie Mellon University (the “CMU License Agreement”). Under the CMU License Agreement, Carnegie Mellon University (“CMU”) granted the Company an exclusive, worldwide right to the PATrOL™ technology, with patents and patent applications describing composition of matter and uses of the platform.

As partial consideration for the license right, Legacy NeuBase issued and delivered to CMU 820,000 shares of Legacy NeuBase’s common stock, which constituted 8.2% of the then fully-diluted capitalization of Legacy NeuBase. Further, as partial consideration for the license right, Legacy NeuBase issued a warrant to CMU, exercisable only upon the earlier of (i) the day that Legacy NeuBase received cumulative capital funding or revenues equal to $2 million or (ii) 30 days prior to any change of control event that provided for the issuance of shares, for a number of shares of Legacy NeuBase common stock sufficient such that when added to the 820,000 shares of Legacy NeuBase’s common stock, CMU would hold in the aggregate an amount equal to 8.2% of then fully-diluted capitalization of Legacy NeuBase; provided, however, that for purposes of calculating 8.2%, only the first $2 million of capital funding was considered in the determination of Legacy NeuBase’s fully-diluted capitalization, (the “CMU Warrant”). The CMU Warrant had an aggregate exercise price of $10.00. Under the CMU License Agreement, CMU has preemptive rights with respect to certain future sales of securities by Legacy NeuBase for capital-raising purposes, “piggyback” registration rights and co-sale rights with respect to certain resales of shares of Legacy NeuBase by Legacy NeuBase’s stockholders.

The Company’s unaudited interim condensed financial statements and related disclosures as of, and for the three months ended, December 31, 2018 (the “Fiscal Q1 2019 Quarterly Financials”) previously accounted for the acquisition of the PATrOL™ technology license as the acquisition of a license and the license was capitalized as an intangible asset. The fair value of the common stock and warrant consideration transferred for the license was initially estimated using the per share price observed in Legacy NeuBase’s private placement commitments entered into with prospective investors, which was approximately $1.61 per share of Legacy NeuBase common stock. The aggregate value of the capitalized license was approximately $1.5 million.

In November 2019, the Company determined that the PATrOL™ technology license did not meet the criteria to be capitalized as it had not achieved regulatory approval, and as the PATrOL™ technology license was the only identified asset in the transaction, the consideration paid for the license should be expensed as in-process research and development. Additionally, the Company engaged a third party valuation firm to value the Company’s common stock and warrants issued in exchange for the license and the Company identified all components of consideration transferred, including cash consideration of approximately $0.05 million and acquisition costs of approximately $0.04 million. The fair value of Legacy NeuBase common stock and warrants issued in exchange for the license was determined to be approximately $0.8 million and $0.1 million, respectively, based upon a fair value of the Company’s common stock of $1.03 per share. 

The consideration paid for the license right is as follows:

 

 

 

 

Cash consideration

    

$

54,000

Acquisition costs

 

 

43,463

Fair value of common stock

 

 

844,600

Fair value of warrant liability issued

 

 

104,902

Total consideration

 

$

1,046,965

 

The correction of the accounting treatment and valuations associated with the PATrOL™ technology license resulted in a decrease in intangible assets of approximately $1.5 million at December 31, 2018 and an increase in research and development expense- license acquired of approximately $1.0 million for the three months ended December 31, 2018.

Share-Based Compensation

In connection with the valuation adjustments to the PATrOL™ technology license consideration, the Company also determined that valuations pertaining to certain share-based awards, due to their proximity to the valuation of the consideration issued in connection with the PATrOL license, should be adjusted as the share-based awards were initially valued using the per share price observed in Legacy NeuBase’s private placement commitments entered into with prospective investors, which was approximately $1.61 per share of Legacy NeuBase common stock.

The fair value of stock option awards granted in the three months ended December 31, 2018 were recalculated using the Black Scholes option pricing model using a per share-price of $1.03 of Legacy NeuBase common stock. The key assumptions used to estimate the fair value of the stock options granted during the three months ended December 31, 2018 included:

 

 

 

 

    

Three Months Ended

 

 

December 31,

 

 

2018

Expected term of options (years)

 

5.5-6.0

Expected common stock price volatility

 

76%

Risk-free interest rate

 

2.5%

Expected dividend yield

 

 —

 

The correction of the valuations and timing of recognizing the awards granted resulted in a restatement of share-based compensation expense and a net decrease of approximately $0.2 million in share-based compensation expense for the three months ended December 31, 2018.

Legacy NeuBase Common Stock Valuations

The fair value of Legacy NeuBase’s common stock was estimated to be $1.03 per share as of December 31, 2018. In order to determine the fair value, the Company considered, among other things, contemporaneous valuations of the Company’s common stock, the Company’s business, financial condition and results of operations, including related industry trends affecting its operations; the likelihood of achieving a liquidity event, such as an initial public offering, or IPO, or sale, given prevailing market conditions; the lack of marketability of the Company’s common stock; the market performance of comparable publicly traded companies; and U.S. and global economic and capital market conditions.

Restated Amounts

The following tables set forth the effects of the foregoing restatement adjustments on affected line items within the Company’s previously issued unaudited statement of operations for the three months ended December 31, 2018, unaudited balance sheet as of December 31, 2018 and unaudited statement of cash flows for the three months ended December 31, 2018. These tables also include adjustments for certain other immaterial items including the correction of the amortization of the convertible note discount.

Statement of Operations

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended December 31, 2018

 

    

As Previously Reported

 

Adjustments

    

As Restated

 

 

 

 

 

 

 

 

 

 

General and administrative expenses

 

$

620,692

 

$

(198,682)

 

$

422,010

Research and development expenses

 

 

54,459

 

 

(49,583)

 

 

4,876

Research and development expenses- license   acquired

 

 

 —

 

 

1,046,965

 

 

1,046,965

Total operating expenses

 

 

675,151

 

 

798,700

 

 

1,473,851

Loss from operations

 

 

(675,151)

 

 

(798,700)

 

 

(1,473,851)

Interest expense

 

 

(4,521)

 

 

(10,116)

 

 

(14,637)

Total other expenses

 

 

(4,521)

 

 

(10,116)

 

 

(14,637)

Net loss

 

$

(679,672)

 

$

(808,816)

 

$

(1,488,488)

Basic and diluted loss per common share (1)

 

 

(0.13)

 

 

 

 

$

(0.25)

Weighted average shares outstanding (1)

 

 

5,315,870

 

 

 

 

 

5,863,333

 

(1)    As previously reported, basic and diluted loss per common share has been adjusted to reflect the Ohr Acquisition.

Balance Sheet

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2018

 

    

As Previously Reported

 

Adjustments

    

As Restated

Assets

 

 

  

 

 

 

 

 

  

Intangible assets, net

 

$

1,488,301

 

$

(1,488,301)

 

$

 —

Total assets

 

 

1,625,491

 

 

(1,488,301)

 

 

137,190

Liabilities

 

 

  

 

 

 —

 

 

  

Accounts payable and accrued expenses

 

 

164,667

 

 

502

 

 

165,169

Warrant liabilities

 

 

163,356

 

 

(58,454)

 

 

104,902

Convertible notes payable, net

 

 

250,000

 

 

9,614

 

 

259,614

Total liabilities

 

 

578,023

 

 

(48,338)

 

 

529,685

Stockholders’ equity (deficit)

 

 

  

 

 

 —

 

 

  

Additional paid-in capital (1)

 

 

1,768,659

 

 

(631,147)

 

 

1,137,512

Accumulated deficit

 

 

(721,624)

 

 

(808,816)

 

 

(1,530,440)

Total stockholders’ equity (deficit)

 

 

1,047,468

 

 

(1,439,963)

 

 

(392,495)

Total liabilities and stockholders’ equity (deficit)

 

$

1,625,491

 

$

(1,488,301)

 

$

137,190

 

(1)    As previously reported, additional paid-in capital has been adjusted to reflect the Ohr Acquisition.

Statement of Cash Flows

 

 

 

 

 

 

 

 

 

 

 

 

For the Three Months Ended December 31, 2018

 

    

As Previously

    

 

 

    

 

 

 

 

Reported

 

Adjustments

 

As Restated

Cash flows from operating activities:

 

 

  

 

 

  

 

 

  

Net loss

 

$

(679,672)

 

$

(808,816)

 

$

(1,488,488)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

  

 

 

  

 

 

  

Stock-based compensation

 

 

444,105

 

 

(150,802)

 

 

293,303

Research and development expense - license acquired

 

 

 —

 

 

1,046,965

 

 

1,046,965

Non-cash amortization on convertible notes

 

 

 —

 

 

9,614

 

 

9,614

Non-cash interest expense on convertible notes

 

 

 —

 

 

5,023

 

 

5,023

Changes in operating assets and liabilities

 

 

  

 

 

  

 

 

  

Accounts payable and accrued expenses

 

 

123,170

 

 

(4,521)

 

 

118,649

Other current assets

 

 

 —

 

 

 1

 

 

 1

Net cash used in operating activities

 

 

(112,397)

 

 

97,464

 

 

(14,933)

Cash flows from investing activities

 

 

  

 

 

  

 

 

  

Payment of transaction costs for license acquired

 

 

 —

 

 

(43,463)

 

 

(43,463)

Cash paid for license acquired

 

 

 —

 

 

(54,000)

 

 

(54,000)

Net cash used in investing activities

 

 

 —

 

 

(97,463)

 

 

(97,463)

Cash flows from financing activities

 

 

  

 

 

  

 

 

  

Repurchase of common stock

 

 

(14)

 

 

 —

 

 

(14)

Proceeds from stock subscription

 

 

 1

 

 

(1)

 

 

 —

Net used in financing activities

 

 

(13)

 

 

(1)

 

 

(14)

Net decrease in cash and cash equivalents

 

 

(112,410)

 

 

 —

 

 

(112,410)

Cash and cash equivalents, beginning of period

 

 

249,600

 

 

 —

 

 

249,600

Cash and cash equivalents, end of period

 

$

137,190

 

 

 —

 

$

137,190

 

 

 

  

 

 

  

 

 

  

Non-cash investing and financing activities:

 

 

  

 

 

  

 

 

  

Common stock for research and development expense-license acquired

 

$

1,324,945

 

$

(480,345)

 

$

844,600

Fair value of warrant liability issued for research and development expense- license acquired

 

$

163,356

 

$

(58,454)

 

$

104,902

 

Fair Value Measurements

Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value:

Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date.

Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates.

Financial instruments measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Management’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The use of different assumptions and/or estimation methodologies may have a material effect on estimated fair values. Accordingly, the fair value estimates disclosed or initial amounts recorded may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.

The following tables present the Company’s fair value hierarchy for its warrant liabilities measured at fair value on a recurring basis at December 31, 2019 and September 30, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

Fair Value Measurements 

 

 

as of December 31, 2019

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

Total

Liabilities

 

 

  

 

 

  

 

 

  

 

 

  

Warrant liabilities

 

$

 —

 

$

 —

 

$

1,190,477

 

$

1,190,477

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Fair Value Measurements 

 

 

as of September 30, 2019

 

    

(Level 1)

    

(Level 2)

    

(Level 3)

    

 Total  

Liabilities

 

 

  

 

 

  

 

 

  

 

 

 

Warrant liabilities

 

$

 —

 

$

 —

 

$

496,343

 

$

496,343

 

The fair value of the warrant liabilities were determined using the Black-Scholes option pricing model. The following assumptions were used in determining the fair value of the warrant liabilities :

 

 

 

 

    

 

 

 

As of

 

 

December 31,

 

 

2019

Common stock price volatility

 

84.9% - 86.2%

Risk-free interest rate

 

1.58% - 1.63%

Remaining contractual term (years)

 

2.0 - 2.3

Expected dividend yield

 

 —

 

The change in fair value of the warrant liabilities for the three months ended December 31, 2019 is as follows:

 

 

 

 

Fair value as of September 30, 2019

    

$

496,343

Change in fair value

 

 

694,134

Fair value as of December 31, 2019

 

$

1,190,477

 

As of December 31, 2019 and September 30, 2019, the recorded values of cash and cash equivalents, accounts payable and the insurance note payable approximate fair value due to the short-term nature of these instruments.

Stock-based Compensation

The Company expenses stock-based compensation to employees, non-employees and board members over the requisite service period based on the estimated grant-date fair value of the awards and actual forfeitures. The Company accounts for forfeitures as they occur. Stock-based awards with graded-vesting schedules are recognized on a straight-line basis over the requisite service period for each separately vesting portion of the award. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model, and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. All stock-based compensation costs are recorded in general and administrative or research and development costs in the consolidated statements of operations based upon the underlying individual’s role at the Company.

Operating Leases

Effective October 1, 2019, the Company determines if an arrangement is a lease at inception. Operating leases are included in operating right-of-use (“ROU”) assets and operating lease liabilities on the consolidated balance sheets. Prior to October 1, 2019, the Company recorded rent expense associated with its operating lease on a straight-line basis over the term of the lease.

Lease ROU assets and operating lease liabilities are initially recognized based on the present value of the future minimum lease payments over the lease term at commencement date calculated using the Company’s incremental borrowing rate applicable to the lease asset, unless the implicit rate is readily determinable. ROU assets also include any lease payments made at or before lease commencement and exclude any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recognized on the Company’s condensed consolidated balance sheet. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company accounts for lease and non-lease components as a single lease component for all its leases.

As of December 31, 2019, the Company’s leases had original terms of less than 12 months. The Company does not recognize ROU assets and lease liabilities that arise from leases with an original term of 12 months or less. Rather, the Company recognizes the lease expense on a straight-line basis over the term of the lease.

 Net Loss Per Share

Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, warrants and stock options that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive.

The following potentially dilutive securities outstanding for the three months ended December 31, 2019 and 2018 have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:

 

 

 

 

 

 

 

As of December 31,

 

    

2019

    

2018

Common stock purchase options

 

6,466,966

 

3,337,406

Unvested restricted stock

 

5,000

 

 —

Common stock purchase warrants

 

715,939

 

101,847

Convertible notes

 

 —

 

218,723

 

 

7,187,905

 

3,657,976

 

Recent Accounting Pronouncements

In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company plans to evaluate the impact of this standard on its consolidated financial statements and related disclosures.

In February 2016, the FASB issued ASU 2016-2, Leases. The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The Company adopted this new lease standard on October 1, 2019 using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. The adoption of the new lease standard did not have an impact on the Company’s condensed consolidated financial statements as the Company did not have any leases with original terms longer than 12 months.